Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in the Netherlands – a Markov model

Charles Christian Adarkwah, Afschin Gandjour, Maren Akkerman & Silvia Evers
Objective: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in the Netherlands [ref:1] as well as in other European countries and the United States [ref:2], [ref:3]. Angiotensin-converting enzyme (ACE) inhibitors have a potential to slow down the prog[for full text, please go to the a.m. URL]